Data Year:

For its 2025 fiscal year, BIO-TECHNE Corp, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
James Hippel
Executive Vice President and CFO
Total Compensation $7,027,382 View details Pay Rank By Title In Biotechnology industry #26 View more
Kim Kelderman
President and CEO
Total Compensation $8,151,180 View details Pay Rank By Title In Biotechnology industry #146 View more
William Geist
President, Protein Sciences
Total Compensation $3,139,299 View details Pay Rank By Title In Biotechnology industry #33 View more
Shane Bohnen
Senior Vice President and General Counsel
Total Compensation $1,980,732 View details Pay Rank By Title In Biotechnology industry #32 View more
Matthew McManus
President, Diagnostics and Spatial Biology
Total Compensation $2,846,619 View details Pay Rank By Title In Biotechnology industry #36 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at BIO-TECHNE Corp as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. BIO-TECHNE Corp income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. BIO-TECHNE Corp annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
James Hippel
Executive Vice President and CFO
Total Cash $1,649,163 Equity $5,360,293 Other $17,926 $7,027,382
Kim Kelderman
President and CEO
Total Cash $2,254,917 Equity $5,862,790 Other $33,473 $8,151,180
William Geist
President, Protein Sciences
Total Cash $1,321,226 Equity $1,800,033 Other $18,040 $3,139,299
Shane Bohnen
Senior Vice President and General Counsel
Total Cash $817,478 Equity $1,145,071 Other $18,183 $1,980,732
Matthew McManus
President, Diagnostics and Spatial Biology
Total Cash $1,016,787 Equity $1,809,895 Other $19,937 $2,846,619
For its 2025 fiscal year, BIO-TECHNE Corp, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Kim Kelderman CEO Pay $8,151,181 Median Employee Pay $91,707 CEO Pay Ratio 89:1
For its 2025 fiscal year, BIO-TECHNE Corp, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Alpna Seth, Ph.D. Total Cash $285,422
John L. Higgins Total Cash $300,422
Joseph Keegan, Ph.D. Total Cash $275,422
Judith Klimovsky, M.D. Total Cash $275,346
Julie L. Bushman Total Cash $292,922
Randolph C. Steer, M.D., Ph.D Total Cash $31,380
Robert V. Baumgartner Total Cash $400,422
Roeland Nusse, Ph.D. Total Cash $290,422
Rupert Vessey, MA, BM BCh, FRCP, DPhi Total Cash $275,422
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.